405224-24-0

Basic information

• Product Name: 5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YLAMINE
• Synonyms: 5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YLAMINE;3-Amino-5-bromo-1H-pyrazolo[3,4-B]pyridine;3-Amino-5-bromo-1H-pyrazo...;5-Bromo-1H-pyrazolo[3,4-b]pyridin-3-amine, 3-Amino-7-aza-5-bromo-1H-indazole;1H-Pyrazolo[3,4-b]pyridin-3-aMine,5-broMo-;5-Bromo-1H-pyrazole[3,4-b]pyridin-3-amine;5-bromo-1H-pyrazolo[3,4-b]pyridine-3-amine
• CAS NO: 405224-24-0
• Molecular Formula: C₆H₅BrN₄
• Molecular Weight: 213.03
• Mol File: 405224-24-0.mol

Chemical Properties

• Boiling Point: 429.136 °C at 760 mmHg
• Flash Point: 213.334 °C
• Appearance: /
• Density: 1.994
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.824
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.55±0.40(Predicted)
• CAS DataBase Reference: 5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YLAMINE(405224-24-0)
• EPA Substance Registry System: 5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YLAMINE(405224-24-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 405224-24-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YLAMINE is used as a building block for the synthesis of pharmaceuticals due to its unique structure and functional groups. It can be incorporated into the design of new drugs to target various diseases and conditions, enhancing the therapeutic potential of medicinal compounds.
Used in Organic Synthesis:
In the field of organic synthesis, 5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YLAMINE serves as a key intermediate for the preparation of various organic compounds. Its reactivity and structural features make it suitable for use in the synthesis of complex organic molecules, contributing to the advancement of chemical research and development.
Used in Medicinal Chemistry Research:
5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YLAMINE is utilized as a research tool in medicinal chemistry to explore its potential as a therapeutic agent. Its unique structure allows scientists to investigate its interactions with biological targets, providing insights into its possible applications in treating various diseases and conditions.
Used in Drug Discovery:
As a valuable component in drug discovery, 5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YLAMINE is employed in the screening and evaluation of potential drug candidates. Its presence in compound libraries enables researchers to identify promising leads for further optimization and development into effective therapeutic agents.
Used in Chemical Biology:
In the realm of chemical biology, 5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YLAMINE is applied as a probe to study the mechanisms of biological processes. Its unique structure allows it to modulate or interact with specific biological targets, providing valuable information for understanding disease pathways and developing targeted therapies.

InChI:InChI=1/C6H5BrN4/c7-3-1-4-5(8)10-11-6(4)9-2-3/h1-2H,(H3,8,9,10,11)

Upstream product

• 405224-22-8 2-hydroxy-3-cyano-5-bromopyridine 
• 405224-22-8 5-bromo-2-oxo-1,2-dihydropyridine-3-carbonitrile 
• 405224-23-9 5-bromo-2-chloropyridine-3-carbonitrile 

Downstream Products

• 1428799-37-4 5-bromo-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridine-3-amine 
• 1289183-22-7 2-{(R)-1-[6-(3-amino-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl]ethylamino}-5-cyano-N-[(S)-1-(4-fluorophenyl)ethyl]nicotinamide 
• 1289179-33-4 3-[4-(3-amino-1Η-pyrazolo[3,4-b]pyridin-5-yl)-benzylamino]-6-cyano-pyrazine-2-carboxylic acid [1-(3,4-difluoro-phenyl)-ethyl]-amide 
• 1428799-38-5 C₂₈H₂₈N₆O₂ 
• 1428799-42-1 C₂₀H₂₄BrN₅O 
• 1392150-47-8 5-(3,5-difluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-amine 
• 1239467-07-2 C₁₄H₈BrF₃N₄O 
• 1239467-03-8 C₁₄H₁₁BrN₄O 
• 1239467-11-8 C₁₄H₁₁BrN₄O₂ 
• 1239467-12-9 C₁₅H₁₃BrN₄O₃ 
• 1239467-02-7 C₁₄H₁₁BrN₄O 

Relevant articles and documents

Pyrazolopyridine hydroxamic acid compound as well as preparation method and application thereof

The invention relates to the technical field of chemical synthesis, in particular to a pyrazolopyridine hydroxamic acid compound as well as a preparation method and application thereof. The pyrazolopyridine hydroxamic acid compound comprises a compound as shown in a formula (1), an isomer thereof, and a hydrate thereof or a pharmaceutically acceptable salt thereof, wherein n is an integer, and R is any one of a substituted or unsubstituted aromatic ring group and a substituted alkyl group. The compound can well inhibit cancer cell proliferation, and then has an excellent treatment effect on tumors.

BETA-LACTAMASE INHIBITORS

Described herein are compounds and compositions that modulate the activity of beta -lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYSNTHESIS FOR BACTERIAL INFECTIONS

The present invention relates to novel heterocyclic compounds which specifically inhibit bacterial FabI and can be used for the treatment of Staphylococcal infections.

A Casein kinase 1/Checkpoint kinase 1 pyrazolo-pyridine protein kinase inhibitor as novel activator of the p53 pathway

Reactivation of the wild-type p53 pathway is one key goal aimed at developing targeted therapeutics in the cancer research field. Although most p53 protein kinases form 'p53-activating' signals, there are few kinases whose action can contribute to the inhibition of p53, as Casein kinase 1 (CK1) and Checkpoint kinase 1 (CHK1). Here we report on a pyrazolo-pyridine analogue showing activity against both CK1 and CHK1 kinases that lead to p53 pathway stabilisation, thus having pharmacological similarities to the p53-activator Nutlin-3. These data demonstrate the emerging potential utility of multivalent kinase inhibitors.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYNTHESIS FOR BACTERIAL INFECTIONS

The present invention relates to novel heterocyclic compounds which specifically inhibit bacterial Fab I and can be used for the treatment of Staphylococcal infections.

Design and synthesis of 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles and pyrazolo[3,4-b]pyridines for Aurora-A kinase inhibitors

Two series of 3-aminopyrazole compounds including 24 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles and 16 pyrazolo[3,4-b]pyridines were synthesized and evaluated against HCT116, A549, and A2780 tumor cell lines. Among them, three compounds were found to have the ideal anti-proliferative activities in vitro. Docking experiments showed that the novel pyrazolo[3,4-b]pyridines share the similar interaction mode with Aurora-A kinase as PHA739358.

HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF

The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders

AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES

The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. Formula (I):

Pyrazolopyridines and pyrazolopyridazines as antidabetics

The present invention includes compound of formula (I), or a derivative thereof, wherein Y is CH or N; R1 is unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted cycloalkenyl, unsubstituted or substituted aryl, aralkyl wherein the aryl and the alkyl moieties may each independently be unsubstituted or substituted, aralkenyl wherein the aryl, and alkenyl moieties may each independently be unsubstituted or substituted, unsubstituted or substituted heterocyclyl, or heterocyclylalkyl wherein the heterocyclyl and the alkyl moieties may each independently be unsubstituted or substituted; and R2 is unsubstituted aryl or unsubstituted or substituted or substituted heteroaryl. Additionally the present invention includes a process for preparing such a compound, a pharmaceutical composition containing such a compound, and the use of such a compound in medicine.